DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Celiac Disease (CD)-Market Insights, Epidemiology and Market Forecast - 2023 - United States" drug pipelines to their offering.
United States Celiac Disease (CD)- Market Insights, Epidemiology and Market Forecasts, 2023 report provides an overview of the disease and global market size of the Celiac Disease for the United States. It also includes historical and forecasted epidemiological data for the diagnosed prevalent cases of Celiac Disease in the U.S. from 2013-2023.
Celiac disease is a genetic autoimmune disease where the indigestion of gluten leads to damage in the small intestine. The number of ways celiac disease can affect patients, combined with a lack of training in medical schools and primary care residency programs, contributes to the poor diagnosis rate.
Currently it is estimated that 80% of the celiac disease population remains undiagnosed. Prevalence in the United States ranges between 1 in 250. It is higher in relatives of people with celiac disease. Women are affected more commonly than men, but there is no age predilection. Our forecasts predict that the total prevalent cases of Celiac Disease is expected to attenuate up to 0.2 Million by 2023 at a negative Compound Annual Growth Rate (CAGR) of 2.23%
There is no targeted therapy approved for celiac disease. The current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases. Owing to the expected launch of Larazotide Acetate (Innovate Pharmaceuticals) in 2021 followed by the launch of Latiglutenase (ImmunogenX/Abbvie) in 2023, shall lead to a hike in the otherwise stable, U.S. market size of celiac disease. Our estimates suggest that the United States market size is expected to grow at a CAGR of 18.5% from 2013-2023.
Key Topics Covered:
- Report Introduction
- Celiac Disease Market Size Overview at a Glance
- Worldwide Market Size of Celiac Disease in 2013
- Worldwide Market Size of Celiac Disease in 2023
- Celiac Disease Overview
- Celiac Disease Types
- Non-Responsive or Refractory CD
- Disease Management
- Disease Treatment
- Treatment of Celiac Disease
- Treatment of Non-Responsive or Refractory Celiac Disease (RCD)
- Current Unmet Medical Needs
- Epidemiology Parameters
- Iceberg Model
- Genetic Predisposition
- Epidemiology &Patient Population
- Diagnosed Prevalent Cases of Celiac Disease in United States (2013-2023)
- Emerging Phase III Therapies
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/5h62wr/celiac_disease